阿托瓦斯塔丁和主动脉硬性在以环素为基础的化疗期间:随机临床试验的二次分析
Vencel Juhasz1,2, Zsofia D Drobni2, Thiago Quinaglia1
1Cardiovascular Imaging Research Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston.
JAMA cardiology
|November 8, 2025
概括
阿托瓦斯塔丁前期治疗在接受 antracycline 化疗的淋巴瘤患者中保留了血管功能,显著降低了大动脉硬度,并预防了不良心血管事件.
科学领域:
- 心血管医学 心血管医学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 人环素是重要的化疗剂,但可以增加血管硬,这是心血管疾病的危险因素.
- 目前没有任何干预措施可以有效地预防与环素相关的血管功能障碍.
研究的目的:
- 为了确定阿托瓦斯塔丁治疗前是否可以减轻由 antracycline 化疗引起的大动脉硬度增加.
主要方法:
- 随机,双盲STOP-CA试验 (NCT02943590) 的二次分析.
- 新诊断的淋巴瘤患者接受阿托瓦斯塔丁 (每天40毫克) 或安慰剂12个月.
- 大动脉脉冲波速 (PWV) 和大动脉延伸能力 (AD) 用心脏MRI测量.
主要成果:
- 阿托瓦斯塔丁组显示PWV稳定 (6.5m/s),而安慰剂组则出现增加 (5.7至6.8m/s).
- 在阿托瓦斯塔丁治疗时,观察到PWV1SD增加的几率显著降低 (5%与50%相比,OR0.05,P<.001).
- 在阿托瓦斯塔丁组中,较少的患者在上升性大动脉延展性下降1SD (7%对18%).
结论:
- 在接受 antracycline 化疗的患者中,阿托瓦斯塔丁的预治疗表明对血管功能有保护作用.
- 这些发现表明,基于证据的潜在策略可以预防化疗引起的心血管并发症.
相关概念视频
01:26Atherosclerosis III: Management
307
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
01:26Coronary Artery Disease IV: Preventive Measures
578
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
578
01:23Atherosclerosis IV: Nursing Management
354
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
354
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
188
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
188
01:27Coronary Artery Disease V: Interprofessional Care
207
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
207
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
377
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
377